{"id":"parecoxib-and-celecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Cardiovascular events (thrombotic)"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These are selective COX-2 inhibitors (coxibs) that preferentially block COX-2 over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing gastric protection from COX-1 inhibition. Parecoxib is the intravenous prodrug of valdecoxib, while celecoxib is an oral selective COX-2 inhibitor. Both are used for acute pain and inflammatory conditions.","oneSentence":"Both parecoxib and celecoxib selectively inhibit cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:52.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute postoperative pain (parecoxib)"},{"name":"Rheumatoid arthritis (celecoxib)"},{"name":"Osteoarthritis (celecoxib)"},{"name":"Acute pain and fever (both agents)"}]},"trialDetails":[{"nctId":"NCT07154433","phase":"NA","title":"A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-01","conditions":"Ankle (Ligaments); Instability (Old Injury), Ankle Sprain, Talus Osteochondral Defect","enrollment":110},{"nctId":"NCT07414706","phase":"PHASE3","title":"Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2026-03","conditions":"Intravenous Lidocaine, Laparoscopic Surgery, Post Operative Recovery","enrollment":182},{"nctId":"NCT06420388","phase":"NA","title":"2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy","status":"RECRUITING","sponsor":"E-DA Hospital","startDate":"2023-05-01","conditions":"Surgery, Pain, Postoperative","enrollment":400},{"nctId":"NCT04314505","phase":"PHASE4","title":"Opioid-Sparing Protocol Comparing With Opioid-based Protocol After Bilateral Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2020-03-20","conditions":"Knee Replacement, Postoperative Pain, Opioid Use","enrollment":56},{"nctId":"NCT03059238","phase":"PHASE3","title":"Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-09","conditions":"Liver Cancer, Pain Postoperative","enrollment":213},{"nctId":"NCT02198924","phase":"PHASE4","title":"Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2014-12","conditions":"Pain, Inflammation","enrollment":246},{"nctId":"NCT02408146","phase":"NA","title":"The Effect of Parecoxib Sodium Intravenous Patient-controlled Analgesia in Laparotomic Liver Resection","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2014-01","conditions":"Pain, Postoperative","enrollment":80},{"nctId":"NCT01930318","phase":"PHASE4","title":"Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2013-08","conditions":"Gastrointestinal Cancer","enrollment":164}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Parecoxib and Celecoxib","genericName":"Parecoxib and Celecoxib","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Both parecoxib and celecoxib selectively inhibit cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain. Used for Acute postoperative pain (parecoxib), Rheumatoid arthritis (celecoxib), Osteoarthritis (celecoxib).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}